HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

EU Commission Wants Expert Opinion On Prostaglandin Analogs In Eyelash Growth Cosmetics

Executive Summary

The Scientific Committee on Consumer Safety will consider available safety data for prostaglandin analogs isopropyl cloprostenate, ethyl tafluprostamide and others with known use in eyelash-growth cosmetic products in the EU. Currently, the substances are not restricted in cosmetic products.

You may also be interested in...



EU's Highest Court Advised Prostaglandin Eyelash Serum Is Not A Medicine Per Se

Just because the use of a substance in a cosmetic product, in this case prostaglandin-derivative methylamide-dihydro-noralfaprostal, has a physiological effect does not mean it's a medicinal product by function, advises the Advocate General of the Court of Justice of the EU in a recent opinion. While the opinion does not bind the CJEU to any decision, it may impact discussions elsewhere with regards to these substances, for example in the US.

CIR Expert Panel Announces New Blood Ahead Of 161st Meeting

Expect new faces in coming meetings of the US-based CIR’s Expert Panel for Cosmetic Ingredient Safety, which may tackle reviews of prostaglandin analogs and skin-lightening kojic acid on top of its usual slate of programmed safety assessments.

CIR Panel Throws Up Hands At Airbrush Ingredient Safety, Defers To FDA On Eyelash ‘Enhancers’

The US-based Cosmetic Ingredient Review’s independent experts finalized four ingredient safety reports at its 7-8 March meeting, advanced nine tentative assessments, and issued two insufficient data announcements. The panel continues to face challenges in assessing ingredients used in airbrush applications and decided against prioritizing review of eyelash-"enhancing" prostaglandin analogues.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

RS150915

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel